iRadimed Q2 Adjusted EPS $0.36 Beats $0.31 Estimate, Sales $16.13M Beat $15.65M Estimate
Portfolio Pulse from Benzinga Newsdesk
iRadimed reported Q2 earnings of $0.36 per share, beating the analyst consensus estimate of $0.31 by 16.13%. This is a 38.46% increase over earnings of $0.26 per share from the same period last year. The company also reported quarterly sales of $16.13 million, beating the analyst consensus estimate of $15.65 million by 3.07%. This is a 26.79% increase over sales of $12.72 million the same period last year.
August 04, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
iRadimed's Q2 earnings and sales exceeded analyst estimates, indicating strong financial performance. This could potentially lead to a positive impact on the company's stock price.
iRadimed's Q2 earnings and sales have exceeded analyst estimates, which is typically a positive signal for investors and can lead to an increase in the company's stock price. The significant YoY growth in earnings and sales further strengthens this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100